---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-008375"
form_type: "8-K"
ticker: "LAB"
cik: "0001162194"
company_name: "STANDARD BIOTOOLS INC."
filed_at: "2026-01-30T23:59:59+00:00"
generated_at: "2026-05-16T05:55:33.746324+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Standard BioTools completes SomaLogic sale to Illumina for up to $425M; holds ~$550M cash

## Summary
- Received $350M upfront cash at closing; eligible for up to $75M in earnout payments based on 2025-2026 revenue targets.
- Post-close cash and equivalents estimated at ~$550M, excluding potential earnouts, to fund inorganic growth.
- Retained mass cytometry and microfluidics businesses; continuing operations on track for positive adjusted EBITDA in 2026.
- Company to receive 2% royalty on SOMAmer-based NGS kit sales for 10 years and a co-exclusive license for singleplex assays.
- Transaction marks strategic exit from aptamer/proteomics business; management plans disciplined M&A to accelerate growth.

## SEC filing metadata
- accession: 0001104659-26-008375
- form_type: 8-K
- ticker: LAB
- cik: 0001162194
- company_name: STANDARD BIOTOOLS INC.
- filed_at: 2026-01-30T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.01, 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1162194/000110465926008375/0001104659-26-008375-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1162194/000110465926008375/tm264472d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-008375
- JSON: https://secwatch.observer/filing/0001104659-26-008375.json
- Plain text: https://secwatch.observer/filing/0001104659-26-008375.txt

## Source-grounded claims
- claim_id: ea0d23c25d696cd1ee0117a221070fafec527f69
  claim: STANDARD BIOTOOLS INC. completed a disposition involving Illumina, Inc. for $350 million in upfront cash and up to $75 million in earnout payments for aggregate cash consideration of up to $425 million (closed 2026-01-30).
  evidence_excerpt: which are being retained by the Company. Under the terms of the Purchase Agreement, Purchaser acquired the Shares for aggregate cash consideration of up to $425 million, comprising (i) an upfront payment of $350 million in cash, which was paid at the closing of the Transaction, as adjusted in accordance with the terms of the Purchase Agreement
  evidence_url: https://www.sec.gov/Archives/edgar/data/1162194/000110465926008375/0001104659-26-008375-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.